Journal article
Increasing incidence of hospitalisation for sport-related concussion in Victoria, Australia
CF Finch, AJ Clapperton, P McCrory
Medical Journal of Australia | AUSTRALASIAN MED PUBL CO LTD | Published : 2013
DOI: 10.5694/mja12.11217
Abstract
Objective: To describe trends in hospitalisation for sport-related concussion. Design, setting and patients: Analysis of routinely collected hospital admissions data from all Victorian hospitals (public and private) over the 2002-03 to 2010-11 financial years for patients aged ≥15 years with a diagnosis of concussion and an ICD-10-AM external cause activity code indicating sport. Main outcome measures: Number and cost of hospitalisations; rate of hospitalisation per 100000 participants overall and for specific sports; and percentage change in frequency and hospitalisation rate per 100000 participants over 9 years. Results: There were 4745 hospitalisations of people aged ≥15 years for sport-r..
View full abstractGrants
Funding Acknowledgements
Caroline Finch receives, or has previously received, competitive research funding from the following bodies for research into concussion or head injury in sport and its prevention: NHMRC, Australian Research Council (ARC), IOC, International Rugby Board (IRB), Australian Football League Research Board (AFLRB), Australian Rugby Union, SRV and the Victorian Health Promotion Foundation (VicHealth). Paul McCrory currently receives financial research support from the NHMRC, University of Melbourne, IOC, SRV and Eastern Health; his previous competitive grant funding includes the ARC, IRB, University of Melbourne, University of Otago, National Hockey League (US), VicHealth, AFLRB, Royal Australasian College of Surgeons, and the Australian Sports Commission. He has received travel funding from, the Medical Commission of the IOC, the Federation Internationale de Football Association (FIFA), the American Academy of Neurology and the Jockey Club (UK). He receives book royalties from McGraw-Hill and from 2001 to 2008 was employed by the BMJ Publishing Group. He has conducted clinical drug trials on antimigraine (Glaxo Wellcome, Janssen-Cilag, Novartis, Parke-Davis; Schering) and antispasticity drugs (Ipsen) through the Eastern Clinical Research Unit in Melbourne. This drug trial work has not involved any financial payment to him directly. He received consultancy fees in 2010 from Axon Sports (US) for the development of educational material (which was not renewed) and has received support since 2005 from CogState Inc for research costs and the development of educational material. He is a cofounder and shareholder in two biomedical companies (involved in e-health and compression garment technologies) but does not hold any individual shares in any company related to concussion or brain injury assessment or technology. Angela Clapperton has no relevant disclosures.